SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001664710-23-000028
Filing Date
2023-05-04
Accepted
2023-05-04 16:01:54
Documents
13
Period of Report
2023-05-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kros-20230504.htm   iXBRL 8-K 47050
2 EX-99.1 exhibit991q12023.htm EX-99.1 65413
  Complete submission text file 0001664710-23-000028.txt   266210

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kros-20230504.xsd EX-101.SCH 1899
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kros-20230504_lab.xml EX-101.LAB 25848
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kros-20230504_pre.xml EX-101.PRE 13579
7 EXTRACTED XBRL INSTANCE DOCUMENT kros-20230504_htm.xml XML 12259
Mailing Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421
Business Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421 617-314-6297
Keros Therapeutics, Inc. (Filer) CIK: 0001664710 (see all company filings)

IRS No.: 811173868 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39264 | Film No.: 23888483
SIC: 2834 Pharmaceutical Preparations